Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exact Sciences Corporation
  6. News
  7. Summary
    EXAS   US30063P1057

EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
39.56 USD   -3.77%
08/10TRANSCRIPT : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medtech Innovations Summit 2022, Aug-10-2022 01:00 PM
CI
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Technology, DuPont de Nemours...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Value Index

06/24/2022 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Value Index


© S&P Capital IQ 2022
All news about EXACT SCIENCES CORPORATION
08/10TRANSCRIPT : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medtech Innovatio..
CI
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Techno..
MS
08/03Craig Hallum Lowers Exact Sciences Price Target to $60 From $81, Maintains Buy Rating
MT
08/03BTIG Adjusts Price Target on Exact Sciences to $70 From $100, Reiterates Buy Rating
MT
08/03Cowen Adjusts Price Target on Exact Sciences to $67 From $83, Keeps Outperform Rating
MT
08/03Baird Adjusts Price Target on Exact Sciences to $75 From $90, Keeps Outperform Rating
MT
08/03Raymond James Adjusts Price Target on Exact Sciences to $70 From $80, Keeps Outperform ..
MT
08/03Citigroup Adjusts Price Target on Exact Sciences to $50 From $65, Maintains Neutral Rat..
MT
08/03MDxHealth Agrees to Buy Exact Sciences' Prostate Cancer Unit for Up to $100 Million
MT
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 2 013 M - -
Net income 2022 -757 M - -
Net Debt 2022 1 950 M - -
P/E ratio 2022 -9,31x
Yield 2022 -
Capitalization 7 001 M 7 001 M -
EV / Sales 2022 4,45x
EV / Sales 2023 3,97x
Nbr of Employees 6 460
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 39,56 $
Average target price 70,63 $
Spread / Average Target 78,5%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Paul J. Limburg Co-Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT SCIENCES CORPORATION-49.17%7 001
GUARDANT HEALTH, INC.-48.59%5 256
BGI GENOMICS CO., LTD.-29.37%3 749
IOVANCE BIOTHERAPEUTICS, INC.-33.00%2 018
ADAPTIVE BIOTECHNOLOGIES CORPORATION-58.84%1 650
VERACYTE, INC.-45.19%1 616